April 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.
February 2007 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.
April 2013 in “The Journal of Urology” Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
April 2019 in “Turkderm” Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.
18 citations
,
May 2008 in “British Journal of Dermatology” Finasteride works better for hair loss in patients 26 or younger.
June 2006 in “American Journal of Epidemiology” Long-term diabetes is linked to lower prostate cancer risk.
October 2017 in “Universidad Nacional de Trujillo” Low doses of Coffea arabica seed extract prevent prostate growth and lower uric acid and PSA levels.
72 citations
,
June 2008 in “The Journal of urology/The journal of urology” Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
1 citations
,
May 2013 in “Journal of the Egyptian Women's Dermatologic Society (Print)” PSA could be a marker for hyperandrogenism in women, but more research is needed.
January 2023 in “International Journal of Clinical and Medical Education Research” Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.
6 citations
,
January 2020 in “The Aging Male” Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.
228 citations
,
February 2003 in “Urology” Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
16 citations
,
April 2007 in “Journal of Obstetrics and Gynaecology Research” Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.
15 citations
,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
4 citations
,
November 2002 in “BJUI” Finasteride treats hair loss but may affect prostate cancer detection.
1 citations
,
February 2022 in “European Journal of Pharmacology” Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
December 2023 in “Research and reports in urology” A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.
April 2022 in “Diabetes Therapy” Low testosterone does not prevent prostate cancer in men with type 1 diabetes.
January 2011 in “Reactions Weekly” St. John's Wort may reduce the effectiveness of finasteride by increasing its breakdown in the body.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
24 citations
,
February 2012 in “Prostate cancer and prostatic diseases” 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
23 citations
,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
16 citations
,
January 2019 in “Pharmaceutical biology” Lespedeza cuneata extract may help treat enlarged prostate.
109 citations
,
April 2000 in “European Urology” Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
77 citations
,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.